Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.50
Bid: 17.00
Ask: 18.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.882%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 17.50
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing and update

22 May 2012 11:30

CERES MEDIA INTERNATIONAL PLC ("Ceres" or the "Company" or the "Group") Placing, update and grant of options Placing

The board announces that the Company, through its broker First Columbus LLP, has placed 21,000,000 new ordinary shares at a price of 1 pence per share ("the Placing Price") raising £210,000 of funds before expenses ("the Placing").

The proceeds of the Placing will be used for general working capital purposes and to support further development of the business.

The Company currently has authority to issue 10,324,556 new ordinary shares for cash and will therefore execute the Placing in two tranches.

The first tranche of 10,000,000 new ordinary shares will occur with immediate effect. Application has been made to the London Stock Exchange for the 10,000,000 new ordinary shares to be admitted to trading on AIM. Trading in these shares is expected to occur on or around 28 May 2012.

Admission of the remaining 11,000,000 new ordinary shares will occur in a second tranche, subject to shareholder approval of further authorities to issue new ordinary shares in the Company for cash. A circular convening a general meeting of the Company ("the General Meeting") will shortly be posted to shareholders seeking, inter alia, such authority.

Proposed Directors' Dealing

The directors of the Company are participating in the second tranche of the Placing, details of each of the directors' participation in the Placing are set out in the table below.

In addition to their participation in the Placing, the directors have agreed to convert certain accrued remuneration costs and unpaid expenses of £84,000 in to 8,400,000 new shares in the Company at the Placing Price ("the Conversion"). Details of the Conversion are set out in the table below. The Conversion will constitute a related party transaction pursuant to the AIM Rules. Shareholders consent in relation to the Conversion will be sought at the General Meeting. A further announcement detailing the related party disclosure will be made subsequent to the General Meeting.

Conditional on shareholder approval at the General Meeting the Company willissue a further 2,000,000 shares in the Company, at the Placing Price, tocertain other creditors in lieu of balances totalling £20,000 ("CreditorConversion").Director Number of Number of Number of Number of % of existing shares Conversion shares enlarged shares held subscribed shares following issued share for in the Placing and capital* Placing Conversion A Dowdeswell 3,527,342 2,617,000 3,000,000 9,144,342 14.9% L Barber 403,089 300,000 4,500,000 5,203,089 8.5% C Garston 379,938 283,000 900,000 1,562,938 2.5%

*assuming the Placing, Conversion and Creditor Conversion occur

Application for admission to trading on AIM of the second tranche of the Placing, the Conversion shares and the Creditor Conversion shares, totalling 21,400,000 new ordinary shares, will occur following the General Meeting.

Following the Placing, Conversion and Creditor Conversion, the so enlarged issued share capital of the Company will comprise 61,373,961 ordinary shares of 1 pence each.

Update

The directors are encouraged by the Group's trading performance since 31 January 2012. As announced on 30 April 2012, the directors remain cautiously optimistic evidenced by the gradual increase in turnover recorded to date in 2012. Orders received in April 2012 were in excess of the total revenues for the 6 months to 31 January 2012.

Sales of NatureWovenTM, ChorusTM and GossypTM, whilst still small by comparison to what the directors believe is their potential, have continued to customers in both the USA and Europe. Additional orders have been received for Nature Netting, the Company's new screening product, for high profile events taking place in the UK during the summer and beyond.

The directors believe that the technical issues surrounding the physical fixing process for the Group's TierraFilmTM Window Cling product have been resolved and this upgraded product is expected to be available in the UK and the USA in June 2012.

Advanced stage testing of the TierraFilmTM Backlit product continues with major `Out of Home' media owners and the Company anticipates approvals shortly. This product boasts excellent print quality combined with superior light diffusion characteristics compared to existing materials used.

Leslie Barber, Chairman, commented: "The indications are that the Company's product portfolio now meets the quality, usage and price requirements of the marketplace and the relevant user base. Distribution gains in the USA and Europe are beginning to show through in sales and the response to NatureNettingTM and BackLit products in the UK is encouraging. The Company looks poised to exploit its unique compostable, recyclable and bio-degradable products in its core markets."

Grant of options

Since the Company's admission to AIM on 13 September 2011, it has agreed to grant options over 960,000 shares ("Admission Options") to directors and key senior management. The terms of the Admission Options are set out below:

Vesting period: None

Exercise period: Any time until 13 September 2020

Exercise price: 1p

Performance criteria: Company's share price in excess of 5 pence per share

Directors' participation in the Admission Options is set out in the table below.

In December 2011, the Company agreed in principal to issue further options to non-executive directors ("Further Options") with the objective of conserving cash resources. Conditional on the granting of the Further Options, the non-executive directors have agreed to waive the cash element of their remuneration and convert existing remuneration liabilities into shares in the Company.

The terms of the Further Options are set out below:

Vesting period: None

Exercise period: Any time until 13 September 2020

Exercise price: 1p

Performance criteria: None

Directors' participation in the Further Options is set out in the table below.

Director Admission Further Total Options Options A Dowdeswell 500,000 nil 500,000 L Barber 300,000 2,500,000 2,800,000 C Garston nil 1,000,000 1,000,000 Others 160,000 nil 160,000

With the exception of the options granted to C Garston, which are issued by way of an unapproved scheme, all other options are issued under an EMI scheme.

The grant of the Admission Options and Further Options to directors is a related party transaction pursuant to the AIM Rules. Shareholder consent in relation to the grant of the Admission Options and Further Options will be sought at the General Meeting. A further announcement detailing the related party disclosure in relation to the options will be made subsequent to the General Meeting.

For further information, please contact:

Ceres Media International PLC Tel: 020 3178 5622 Alex Dowdeswell / Leslie Barber Nominated Adviser - Cairn Financial Advisers LLP Tel: 020 7148 7900 Jo Turner / Liam Murray Broker - First Columbus LLP Tel: 020 3002 2070

Chris Crawford / Kelly Gardiner

Date   Source Headline
30th Apr 20247:00 amRNSManufacturing agreement with KAG Industries
15th Apr 20248:49 amRNSHolding(s) in Company
25th Mar 20247:00 amRNSPlacing, Subscription and Director Dealing
18th Mar 202411:36 amRNSHolding(s) in Company
13th Mar 20247:00 amRNSPartnership agreement with Morepen for SlimBiome
8th Mar 20244:09 pmRNSHolding(s) in Company
27th Feb 20247:00 amRNSStrategic and commercial update
9th Feb 20247:00 amRNSChange of auditor
5th Feb 20247:00 amRNSPresentation at ProBiota 2024
30th Jan 20247:00 amRNSSweetBiotix Update
15th Jan 20247:00 amRNSLaunch of LeanBiome in Muscletech
4th Dec 20237:00 amRNSDirectorate Change
28th Nov 20237:00 amRNSDistribution agreement for SlimBiome
24th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 20237:00 amRNSBBSRC Grant for WellBiome®
1st Nov 20237:00 amRNSCommercial update
23rd Oct 20237:00 amRNSLicense agreement with Tata Chemicals
19th Oct 20233:02 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSHalf-year Report
22nd Sep 20237:00 amRNSPlanned launch of OptiBiotix products with Boots
29th Aug 20237:00 amRNSCommercial update
31st Jul 202312:51 pmRNSHolding(s) in Company
26th Jul 202312:34 pmRNSResult of AGM
19th Jul 20237:00 amRNSSweetBiotix® overview
28th Jun 20237:00 amRNSFinal Results
4th May 20237:00 amRNSInvestor update
21st Mar 20237:00 amRNSChange of Broker
15th Mar 20237:00 amRNSSlimbiome study results
21st Feb 20237:00 amRNSDirectorate Change
30th Jan 20234:28 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIssue of Equity – Subscription
10th Nov 202211:30 amRNSInvestor update
1st Nov 20227:00 amRNSLaunch of GoFigure products on Tmall China
24th Oct 20227:00 amRNSApproval of GoFigure products
17th Oct 20227:00 amRNSNew health claims for SlimBiome in Australia
17th Oct 20227:00 amRNSNew health claims for SlimBiome in Australia
28th Sep 20227:00 amRNSHalf-year Report
26th Sep 20227:00 amRNSLaunch of novel prebiotic in Europe and Africa
20th Sep 20227:00 amRNSLaunch of GoFigure range with Apollo Hospitals
14th Sep 20227:00 amRNSNew commercialisation partner in Asia Pacific
24th Aug 20224:41 pmRNSSecond Price Monitoring Extn
24th Aug 20224:35 pmRNSPrice Monitoring Extension
24th Aug 20222:06 pmRNSSecond Price Monitoring Extn
24th Aug 20222:00 pmRNSPrice Monitoring Extension
24th Aug 202211:06 amRNSSecond Price Monitoring Extn
24th Aug 202211:00 amRNSPrice Monitoring Extension
24th Aug 20229:05 amRNSSecond Price Monitoring Extn
24th Aug 20229:00 amRNSPrice Monitoring Extension
24th Aug 20227:00 amRNSTrading update
26th Jul 202212:31 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.